395 related articles for article (PubMed ID: 30413412)
21. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Levina V; Su Y; Gorelik E
Clin Dev Immunol; 2012; 2012():173029. PubMed ID: 22654951
[TBL] [Abstract][Full Text] [Related]
22. Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.
She Y; Xu X; Yu Q; Yang X; He J; Tang XX
Respir Res; 2023 Apr; 24(1):118. PubMed ID: 37120511
[TBL] [Abstract][Full Text] [Related]
23. Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions.
Roy S; Bag AK; Dutta S; Polavaram NS; Islam R; Schellenburg S; Banwait J; Guda C; Ran S; Hollingsworth MA; Singh RK; Talmadge JE; Muders MH; Batra SK; Datta K
Cancer Res; 2018 Oct; 78(19):5600-5617. PubMed ID: 30111533
[TBL] [Abstract][Full Text] [Related]
24. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
25. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
26. PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages.
Schilperoort M; Ngai D; Katerelos M; Power DA; Tabas I
Nat Metab; 2023 Mar; 5(3):431-444. PubMed ID: 36797420
[TBL] [Abstract][Full Text] [Related]
27. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
[TBL] [Abstract][Full Text] [Related]
28. The complex roles of efferocytosis in cancer development, metastasis, and treatment.
Tajbakhsh A; Gheibi Hayat SM; Movahedpour A; Savardashtaki A; Loveless R; Barreto GE; Teng Y; Sahebkar A
Biomed Pharmacother; 2021 Aug; 140():111776. PubMed ID: 34062411
[TBL] [Abstract][Full Text] [Related]
29. IDO is a nodal pathogenic driver of lung cancer and metastasis development.
Smith C; Chang MY; Parker KH; Beury DW; DuHadaway JB; Flick HE; Boulden J; Sutanto-Ward E; Soler AP; Laury-Kleintop LD; Mandik-Nayak L; Metz R; Ostrand-Rosenberg S; Prendergast GC; Muller AJ
Cancer Discov; 2012 Aug; 2(8):722-35. PubMed ID: 22822050
[TBL] [Abstract][Full Text] [Related]
30. Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment.
Zhou L; Matsushima GK
Int Rev Cell Mol Biol; 2021; 361():165-210. PubMed ID: 34074493
[TBL] [Abstract][Full Text] [Related]
31. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
32. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
[TBL] [Abstract][Full Text] [Related]
33. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
34. ODC (Ornithine Decarboxylase)-Dependent Putrescine Synthesis Maintains MerTK (MER Tyrosine-Protein Kinase) Expression to Drive Resolution.
Yurdagul A; Kong N; Gerlach BD; Wang X; Ampomah P; Kuriakose G; Tao W; Shi J; Tabas I
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):e144-e159. PubMed ID: 33406854
[TBL] [Abstract][Full Text] [Related]
35. CADHERIN-11 regulation of myeloid phagocytes and autoimmune inflammation in murine lupus.
Chavula T; To S; Smith J; Pedroza M; Nimri J; Devaraj S; Wenderfer S; Vogel TP; Agarwal SK
J Autoimmun; 2024 May; 145():103197. PubMed ID: 38447248
[TBL] [Abstract][Full Text] [Related]
36. IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.
Munn DH; Sharma MD; Johnson TS; Rodriguez P
Cancer Immunol Immunother; 2017 Aug; 66(8):1049-1058. PubMed ID: 28488123
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes.
Suresh Babu S; Thandavarayan RA; Joladarashi D; Jeyabal P; Krishnamurthy S; Bhimaraj A; Youker KA; Krishnamurthy P
Sci Rep; 2016 Nov; 6():36207. PubMed ID: 27827458
[TBL] [Abstract][Full Text] [Related]
38. A Real-Time Image-Based Efferocytosis Assay for the Discovery of Functionally Inhibitory Anti-MerTK Antibodies.
Bravo DD; Shi Y; Sheu A; Liang WC; Lin W; Wu Y; Yan M; Wang J
J Immunol; 2023 Apr; 210(8):1166-1176. PubMed ID: 36881873
[TBL] [Abstract][Full Text] [Related]
39. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
40. RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer.
Zhou X; Li D; Xia S; Ma X; Li R; Mu Y; Liu Z; Zhang L; Zhou Q; Zhuo W; Ding K; Lin A; Liu W; Liu X; Zhou T
J Control Release; 2024 Feb; 366():128-141. PubMed ID: 38104775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
